RGD Peptide‐Drug Conjugates as Effective Dual Targeting Platforms: Recent Advances
نویسندگان
چکیده
منابع مشابه
Tumor angiogenic vasculature targeting with PAMAM dendrimer-RGD conjugates.
PAMAM dendrimer-RGD-4C peptide conjugate was synthesized and in vitro targeting efficacy to integrin receptor expressing cells was studied by flow cytometry and confocal microscopy.
متن کاملBarriers and recent advances in non-viral vectors targeting the lungs for cystic fibrosis gene therapy
Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in CFTR genes that affect chloride ion channel. The CF is a good nominee for gene therapy as the asymptomatic carriers are phenotypically normal, and the desired cells are accessible for vector delivery. Gene therapy shows promising effects involving the correction of gene or replacement of the mutant gene with the func...
متن کاملRecent advances in the synthesis of antibody-drug conjugates
Antibody-drug conjugates (ADCs) are derived from antibodies covalently attached to highly potent drugs using a variety of conjugation and linker technologies. This class of therapeutic conceptually combines the exquisite specificity of antibodies (i.e. enabling discrimination between healthy and diseased tissue) with the cell-killing ability of potent cytotoxic drugs. This powerful and exciting...
متن کاملNGR-peptide−drug conjugates with dual targeting properties
Peptides containing the asparagine-glycine-arginine (NGR) motif are recognized by CD13/aminopeptidase N (APN) receptor isoforms that are selectively overexpressed in tumor neovasculature. Spontaneous decomposition of NGR peptides can result in isoAsp derivatives, which are recognized by RGD-binding integrins that are essential for tumor metastasis. Peptides binding to CD13 and RGD-binding integ...
متن کاملRecent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy
Recent advances in cancer treatment have emerged from new immunotherapies targeting T-cell inhibitory receptors, including cytotoxic T-lymphocyte associated antigen (CTLA)-4 and programmed cell death (PD)-1. In this context, anti-CTLA-4 and anti-PD-1 monoclonal antibodies have demonstrated survival benefits in numerous cancers, including melanoma and non-small-cell lung carcinoma. PD-1-expressi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Organic Chemistry
سال: 2021
ISSN: 1434-193X,1099-0690
DOI: 10.1002/ejoc.202100240